Shortly after taking over as CEO, Claus Kjærsgaard spoke with BioStock about Sigrid’s strategic priorities, with commercial scale-up and market expansion for SiPore® at the centre of the plan.
Media Coverage
Sigrid Therapeutics nya VD på plats – fokus på kommersiell uppskalning
Media: BioStock
Featuring: Claus Kjærsgaard
In an interview with BioStock, new CEO Claus Kjærsgaard sets out Sigrid’s priorities: commercial scaling and market expansion.
Leadership strategyCommercialisationMarket growth


